Roche could this week learn whether the European Medicines Agency will recommend pan-EU marketing approval for mosunetuzumab, the company’s CD20xCD3 T-cell engaging bispecific antibody for treating refractory follicular lymphoma.
If Roche gets the thumbs up, it could become the first company to market a CD20xCD3 bispecific for follicular
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?